Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Osteogenesis imperfecta
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 20 Jan 2017 Planned End Date changed from 1 Jun 2021 to 1 Aug 2021.
- 20 Jan 2017 Planned primary completion date changed from 1 Jun 2019 to 1 Aug 2019.
- 26 Aug 2016 This trial was completed in Czech Republic (end date: 2015-10-22), according to the European Clinical Trials Database.